Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes,
antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs,
therapeutic options are very limited. Alkylating agents showed a modest activity in
pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and
the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients
who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.